Observed | ||||||
---|---|---|---|---|---|---|
Site of cancer (ICD9 code) | All | Male | Female | Expected | SMR | 95% CI |
Including all years of follow up | ||||||
All cancers (140–208) | 58 | 11 | 47 | 31.6 | 1.8 | 1.4 to 2.4 |
Digestive (150–154, 157) | 7 | 1 | 6 | 7.4 | 1.0 | 0.4 to 2.0 |
Liver (155) | 12 | 3 | 9 | 0.3 | 38.6 | 20.0 to 67.5 |
Respiratory (162) | 19 | 4 | 15 | 8.0 | 2.4 | 1.4 to 3.7 |
Breast (174) | 2 | – | 2 | 4.5 | 0.4 | 0.1 to 1.6 |
Reproductive (179–180, 182–183) | 3 | – | 3 | 2.6 | 1.2 | 0.2 to 3.4 |
Urinary (188–189) | 2 | 0 | 2 | 0.3 | 6.6 | 0.8 to 23.6 |
Haematological (200–208) | 7 | 1 | 6 | 1.8 | 3.9 | 1.6 to 8.1 |
Excluding experience in first year after PBC diagnosis | ||||||
All cancers (140–208) | 46 | 9 | 37 | 28.1 | 1.6 | 1.2 to 2.2 |
Digestive (150–154, 157) | 4 | 0 | 4 | 6.5 | 0.6 | 0.2 to 1.6 |
Liver (155) | 11 | 3 | 8 | 0.3 | 39.7 | 19.8 to 71.0 |
Respiratory (162) | 17 | 3 | 14 | 7.1 | 2.4 | 1.4 to 3.8 |
Breast (174) | 1 | – | 1 | 4.0 | 0.3 | 0.01 to 1.4 |
Reproductive (179–180, 182–183) | 3 | – | 3 | 2.3 | 1.3 | 0.3 to 3.9 |
Urinary (188–189) | 1 | 0 | 1 | 0.3 | 3.7 | 0.1 to 20.8 |
Haematological (200–208) | 5 | 1 | 4 | 1.6 | 3.2 | 1.0 to 7.4 |
CI, confidence interval.